Breaking News

Halozyme, Acumen Partner on Technology in Alzheimer’s Disease

Acumen to explore the potential use of ENHANZE drug delivery technology for ACU193, Acumen's clinical-stage monoclonal antibody candidate.

Halozyme Therapeutics, Inc. entered into a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals leveraging Halozyme’s ENHANZE drug delivery technology, a recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery, for a single target. Acumen intends to explore the potential use of ENHANZE for ACU193, Acumen’s clinical-stage monoclonal antibody (mAb) candidate to target Amyloid-β Oligomers (AβOs) for the treatment of earl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters